MedTrace Logo

Impact of Maxigesic on Delirium After Minimally Invasive Lung Surgery in Elderly Patients

NCT05834569 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-09-05

No results posted yet for this study

Summary

The primary aim of this interventional study is to investigate the impact of perioperative administration of Maxigesic (combination of acetaminophen and ibuprofen) on delirium after minimally invasive lung surgery in elderly patients. The Maxigesic group receives a total of 5 doses of Maxigesic (20mg/kg, maximum dose per serving: 1g) every 6 h from immediately after anesthesia induction. The control group receives the same volume of normal saline. Researchers compare the incidence and severity of postoperative delirium for 5 days after surgery.

Conditions

  • Delirium
  • Aged
  • Lung Neoplasms
  • Robotic Surgical Procedures
  • Thoracic Surgery, Video-Assisted

Interventions

DRUG

Acetaminophen and Ibuprofen

Patients in the Maxigesic group will be administered a total of 5 doses of the drug (20mg/kg, maximum dose per serving: 1g) every 6 h from immediately after anesthetic induction.

DRUG

Normal saline

Patients in the control group will be administered equal amounts of normal saline at the same time points.

Sponsors & Collaborators

  • Kyongbo Pharmaceutical Co.,Ltd

    collaborator UNKNOWN

  • Korea University Guro Hospital

    lead OTHER

Principal Investigators

  • Heezoo Kim, MD, PhD · Korea University Guro Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-15
Primary Completion
2025-01-23
Completion
2025-01-23

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05834569 on ClinicalTrials.gov